FDA shares guide on genome editing best practices
The FDA's guidance emphasises the potential of NGS methods to mitigate safety risks associated with therapies incorporating genome editing.
By Pharmaceutical Technology
· Apr 15, 2026
· via Pharmaceutical Technology
Image: Pharmaceutical Technology
Tags
policyformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
PolicyFierceBiotech ↗
China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma ex…
PolicyFierceBiotech ↗
Asked by Fierce if he'd consider returning to the FDA, Pazdur said he wouldn't serve again under the Trump adm…
PolicyBriefing
Using the Kemp-Kasten amendment, the administration withheld $32.5 million in FY2025 UNFPA support and is expe…